The major goal of this proposal is to provide direct evidence (causal relationship) that organ-derived paracrine growth factors regulate the site-specific growth of malignant human colon carcinoma (HCC) cells that possess the appropriate receptors. Recent data from our laboratory demonstrates that the ability of HCC cells to produce hepatic metastasis directly correlates with expression of epidermal growth factor receptor (EGF-R). Highly metastatic HCC cells also respond to specific mitogenic signals produced by tissue undergoing repair (hepatectomy followed by liver regeneration) demonstrating that physiological signals can be utilized by neoplastic cells.
Four specific aims will be pursued. EGF-R, hepatocyte growth factor (c- met), and insulin-like growth factor-1 receptor (IGF-1-R) will be functionally characterized (alone and in combination) in an isogeneic HCC cell system using highly metastatic versus non- and low-metastatic cells growing in vitro, in co-culture with human hepatocytes, and orthotopically, ectopically, or at the metastatic site in athymic nude mice using standard molecular, biochemical and tumor biological techniques. Secondly, the production and putative upregulation of the ligands for these receptors (transforming growth factor alpha (TGF-alpha), hepatocyte growth factor (HGF), and insulin-like growth factor-1 (IGF-1)) will be assessed in host tissue adjacent to the HCC growing at orthotopic, ectopic, and metastatic sites in athymic nude mice using in situ mRNA hybridization (ISH), immunohistochemistry, and reverse transcriptase- polymerase chain reaction (RT-PCR) analyses. Thirdly, to determine if these receptors are directly involved (causal relationship), or alternatively, act as markers for the metastasis and growth of HCC cells in the liver environment, methodologies designed to disrupt the function or decrease the levels of the receptors will be invoked, i.e., antisense RNA, protein tyrosine kinase (PTK) inhibition, and expression of dominant negative mutant receptors. Lastly, fresh and archival primary and metastatic colon carcinoma surgical specimens will be analyzed for expression of EGF-R, c-met, and IGF-1-R by the HCC and production of their corresponding ligands by the adjacent host tissue using mRNA, protein ISH, and immunohistochemical techniques for the relevance of the in vitro and nude mouse findings to clinical reality. The knowledge gained from this research should extend our understanding of host:tumor interactions and provide a therapeutic basis for interfering with hepatic metastases produced by HCC by downregulation of PTK receptor number and function.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA067952-03
Application #
2443160
Study Section
Metabolic Pathology Study Section (MEP)
Project Start
1995-07-15
Project End
2000-06-30
Budget Start
1997-07-01
Budget End
1998-06-30
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Anatomy/Cell Biology
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
MacEwen, E Gregory; Pastor, Josep; Kutzke, Jonathan et al. (2004) IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 92:77-91
MacEwen, E Gregory; Kutzke, Jon; Carew, Jennifer et al. (2003) c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis 20:421-30
Herynk, Matthew H; Tsan, Rachael; Radinsky, Robert et al. (2003) Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin Exp Metastasis 20:291-300
Bruns, C J; Solorzano, C C; Harbison, M T et al. (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60:2926-35
Inoue, K; Slaton, J W; Perrotte, P et al. (2000) Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6:4874-84
Bruns, C J; Harbison, M T; Davis, D W et al. (2000) Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6:1936-48
Inoue, K; Slaton, J W; Davis, D W et al. (2000) Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 6:2635-43
Perrotte, P; Matsumoto, T; Inoue, K et al. (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257-65
Parker, C; Roseman, B J; Bucana, C D et al. (1998) Preferential activation of the epidermal growth factor receptor in human colon carcinoma liver metastases in nude mice. J Histochem Cytochem 46:595-602
Beech, D; Pollock, R E; Tsan, R et al. (1998) Epidermal growth factor receptor and insulin-like growth factor-I receptor expression and function in human soft-tissue sarcoma cells. Int J Oncol 12:329-36

Showing the most recent 10 out of 18 publications